Cagrilintide + Semaglutide: The Amylin/GLP-1 Research Combo
Cagrilintide is an amylin analog studied alongside semaglutide. Here's why the amylin/GLP-1 combination is its own research category.
Most of the metabolic cluster is built from incretin agonists. The cagrilintide + semaglutide combination is different: it pairs two compounds that act on two different receptor systems — amylin and GLP-1 — in a single preparation. That makes it a distinct research category worth understanding on its own terms. For in-vitro laboratory research only.
What is cagrilintide?
Cagrilintide is a synthetic long-acting amylin analog — an agonist at amylin receptors. Amylin is a peptide hormone co-secreted with insulin, and the amylin pathway is studied in research alongside, but separately from, the incretin (GLP-1/GIP) pathways. Cagrilintide is the amylin half of the combination.
What is semaglutide's role here?
Semaglutide is the GLP-1 receptor agonist half of the blend — the same single-agonist GLP-1 compound covered in what is semaglutide. Standalone, the semaglutide reference standard engages the GLP-1 pathway alone; in the combination it brings that incretin arm alongside cagrilintide's amylin arm.
Why combine amylin and GLP-1 agonists?
The rationale is complementary pathways. Amylin and GLP-1 are distinct receptor systems, both studied in appetite-regulation and metabolic models. Combining an amylin agonist with a GLP-1 agonist lets researchers examine whether engaging the two pathways together produces different in-vitro outcomes than either alone — a different research question from the incretin-stacking studied in dual and triple agonists like tirzepatide and retatrutide.
How this differs from a dual incretin agonist
It is easy to confuse this combination with a dual agonist, but the mechanism is different. A dual agonist like tirzepatide is one molecule hitting two incretin receptors (GIP + GLP-1). The cagrilintide + semaglutide blend is two separate molecules hitting two different receptor systems (amylin + GLP-1). One is intramolecular multi-agonism; the other is a co-formulated pair. For the incretin side of that picture, see GLP-1 research peptides explained.
What the combination is studied for
As a reference preparation, the cagrilintide + semaglutide blend is used in research examining amylin and GLP-1 receptor signaling and in appetite-regulation and metabolic models that look at complementary-pathway engagement. It is a frequent subject in studies of multi-pathway metabolic pharmacology.
How the research blend is supplied
The blend ships lyophilized in multi-vial research kits from our US facility within 48 hours with tracking. Reconstitute with bacteriostatic water using the reconstitution calculator, then order the cagrilintide + semaglutide blend or browse the weight & metabolic category.
Frequently asked questions
What is cagrilintide?
Cagrilintide is a synthetic long-acting amylin analog — an agonist at amylin receptors. It is studied as the amylin half of the cagrilintide + semaglutide research combination.
Why is cagrilintide combined with semaglutide?
They act on different receptor systems — amylin and GLP-1. Combining them lets researchers study complementary metabolic pathways in a single preparation, a different mechanism than the incretin-stacking in dual or triple agonists.
Is the cagrilintide + semaglutide blend a dual agonist?
No. A dual agonist is one molecule hitting two incretin receptors. This blend is two separate molecules acting on two different systems (amylin and GLP-1), so it is a co-formulated pair rather than a single multi-agonist molecule.